Tower Bridge Advisors Bristol Myers Squibb CO Transaction History

Tower Bridge Advisors

$900 Billion
Q2 2024

A detailed history of Tower Bridge Advisors transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Tower Bridge Advisors holds 32,890 shares of BMY stock, worth $1.62 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares

32,890

Previous 40,275 18.34%

Holding current value

$1.62 Million

Previous $2.18 Billion 37.46%

% of portfolio

0.15%

Previous 0.22%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 24, 2024	SELL	$40.25 - $52.99 $297,246 - $391,331	-7,385 Reduced 18.34%	32,890 $1.37 Billion
Q1 2024 Apr 29, 2024	SELL	$47.98 - $54.4 $57,192 - $64,844	-1,192 Reduced 2.87%	40,275 $2.18 Billion
Q4 2023 Feb 14, 2024	SELL	$48.48 - $57.85 $332,233 - $396,446	-6,853 Reduced 14.18%	41,467 $2.13 Billion
Q3 2023 Nov 01, 2023	SELL	$57.89 - $64.73 $631,116 - $705,686	-10,902 Reduced 18.41%	48,320 $2.8 Billion
Q2 2023 Jul 20, 2023	SELL	$63.71 - $70.74 $1.98 Million - $2.2 Million	-31,105 Reduced 34.44%	59,222 $3.79 Billion
Q1 2023 Apr 26, 2023	SELL	$65.71 - $74.53 $24,444 - $27,725	-372 Reduced 0.41%	90,327 $6.26 Billion
Q4 2022 Jan 27, 2023	SELL	$68.48 - $81.09 $1,848 - $2,189	-27 Reduced 0.03%	90,699 $6.53 Billion
Q3 2022 Nov 14, 2022	SELL	$0.13 - $76.84 $88 - $52,097	-678 Reduced 0.74%	90,726 $6.45 Billion
Q2 2022 Jul 21, 2022	SELL	$72.62 - $79.98 $163,031 - $179,555	-2,245 Reduced 2.4%	91,404 $7.04 Billion
Q1 2022 May 05, 2022	SELL	$61.48 - $73.72 $341,890 - $409,956	-5,561 Reduced 5.61%	93,649 $6.84 Billion
Q4 2021 Feb 09, 2022	SELL	$53.63 - $62.52 $433,330 - $505,161	-8,080 Reduced 7.53%	99,210 $6.19 Billion
Q3 2021 Oct 28, 2021	SELL	$59.17 - $69.31 $129,700 - $151,927	-2,192 Reduced 2.0%	107,290 $6.35 Billion
Q2 2021 Aug 10, 2021	SELL	$61.91 - $67.42 $722,675 - $786,993	-11,673 Reduced 9.63%	109,482 $7.32 Billion
Q1 2021 May 12, 2021	SELL	$59.34 - $66.74 $4.09 Million - $4.6 Million	-68,859 Reduced 36.24%	121,155 $7.65 Billion
Q4 2020 Feb 11, 2021	BUY	$57.74 - $65.43 $1.5 Million - $1.7 Million	25,920 Added 15.8%	190,014 $11.8 Billion
Q3 2020 Nov 13, 2020	BUY	$57.43 - $63.64 $693,696 - $768,707	12,079 Added 7.95%	164,094 $9.89 Billion
Q2 2020 Jul 22, 2020	BUY	$54.82 - $64.09 $108,927 - $127,346	1,987 Added 1.32%	152,015 $8.94 Billion
Q1 2020 Apr 27, 2020	BUY	$46.4 - $67.43 $234,320 - $340,521	5,050 Added 3.48%	150,028 $8.36 Billion
Q4 2019 Feb 05, 2020	SELL	$49.21 - $64.19 $111,755 - $145,775	-2,271 Reduced 1.54%	144,978 $9.31 Billion
Q3 2019 Nov 12, 2019	SELL	$42.77 - $50.71 $615,759 - $730,071	-14,397 Reduced 8.91%	147,249 $8.54 Billion
Q2 2019 Aug 06, 2019	SELL	$44.62 - $49.34 $1.07 Million - $1.18 Million	-23,978 Reduced 12.92%	161,646 $7.33 Billion
Q1 2019 Apr 30, 2019	BUY	$45.12 - $53.8 $1.16 Million - $1.39 Million	25,776 Added 16.13%	185,624 $8.86 Billion
Q4 2018 Feb 07, 2019	BUY	$48.76 - $63.23 $1.49 Million - $1.93 Million	30,558 Added 23.64%	159,848 $8.31 Billion
Q3 2018 Oct 23, 2018	SELL	$55.19 - $62.25 $41,613 - $46,936	-754 Reduced 0.58%	129,290 $8.03 Billion
Q2 2018 Aug 09, 2018	SELL	$50.53 - $62.98 $228,648 - $284,984	-4,525 Reduced 3.36%	130,044 $7.2 Billion
Q1 2018 May 02, 2018	SELL	$59.92 - $68.98 $3.53 Million - $4.07 Million	-58,950 Reduced 30.46%	134,569 $8.51 Billion
Q4 2017 Jan 30, 2018	SELL	$59.94 - $65.35 $181,678 - $198,075	-3,031 Reduced 1.54%	193,519 $11.9 Billion
Q3 2017 Nov 06, 2017	BUY	$55.23 - $63.74 $10.9 Million - $12.5 Million	196,550	196,550 $12.5 Billion

Others Institutions Holding BMY

# of Institutions

2,400

Shares Held

1.5B

Call Options Held

29.7M

Put Options Held

32.2M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $104B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Bridge Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Tower Bridge Advisors with notifications on news.

Account

Tower Bridge Advisors Bristol Myers Squibb CO Transaction History